LYPD3 antibody (AA 31-245)

Catalog No. ABIN7873757

This Rabbit Polyclonal antibody specifically detects LYPD3 in ELISA, WB, FACS, IHC (p) and IF. It exhibits reactivity toward Human, Mouse and Rat.

Quick Overview for LYPD3 antibody (AA 31-245) (ABIN7873757)

Target: LYPD3 (LY6/PLAUR Domain Containing 3 (LYPD3))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LYPD3 antibody is un-conjugated

Application: ELISA, Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF)

Product Details anti-LYPD3 Antibody

Binding Specificity: AA 31-245

Purpose: LYPD3 Antibody / Ly6/PLAUR domain-containing protein 3

Purification: Antigen affinity purified

Immunogen: An E.coli-derived human recombinant protein (amino acids L31-E245) was used as the immunogen for the LYPD3 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the LYPD3 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the LYPD3 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for LYPD3

Target: LYPD3 (LY6/PLAUR Domain Containing 3 (LYPD3))

Alternative Name: LYPD3

Background: Ly6/PLAUR domain-containing protein 3 is a protein that in humans is encoded by the LYPD3 gene. Ly6 / PLAUR domain-containing protein 3, also known as GPI-anchored metastasis-associated protein C4.4A homolog, Matrigel-induced gene C4 protein, MIG-C4, and LYPD3, is a cell membrane protein that contains two UPAR/Ly6 domains. Human LYPD3 contains two UPAR/Ly6 domains. LYPD3 is expressed in the placenta, skin, and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in the esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression.

UniProt: O95274